Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01072786 · ClinicalTrials.gov registry record · Phase 1
Evaluation of the Safety and Immune Response of Five Admixtures of a Tetravalent Dengue Virus Vaccine
A Phase 1 study, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- Completed
- Registry status
- Phase 1
- Development phase
- 141
- Enrollment target
NCT01072786 is a Phase 1 study that has completed, run by National Institute of Allergy and Infectious Diseases (NIAID). The registered enrollment target is 141 participants.
The verdict
NCT01072786, a Phase 1 study, has completed, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 141 participants
- Enrollment target
Study Summary
Dengue viruses can cause dengue fever and other serious health conditions, primarily affecting people living in tropical regions of the world. This study will evaluate the safety and immune responses of five formulations of a tetravalent dengue virus vaccine in healthy adults.
Interventions
- BIOLOGICAL Placebo
- BIOLOGICAL TetraVax-DV Vaccine-Admixture 1
- BIOLOGICAL TetraVax-DV Vaccine-Admixture 2
- BIOLOGICAL TetraVax-DV Vaccine-Admixture 3
- BIOLOGICAL TetraVax-DV Vaccine-Admixture 4
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 141 participants |
| Start Date | 2010-07 |
| Est. Completion | 2012-06 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01072786
The ClinicalTrials.gov registry entry for NCT01072786 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 141 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Placebo is the first listed.
NCT01072786 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01072786 about?
NCT01072786 is a clinical study titled "Evaluation of the Safety and Immune Response of Five Admixtures of a Tetravalent Dengue Virus Vaccine". Dengue viruses can cause dengue fever and other serious health conditions, primarily affecting people living in tropical regions of the world. This study will evaluate the safety and immune responses of five formulations of a tetravalent dengue virus vaccine in healthy adults.
What is the current status of trial NCT01072786?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 141 participants. The study started on 2010-07. Estimated completion is 2012-06.
What interventions are being tested in trial NCT01072786?
The interventions under investigation include: Placebo (BIOLOGICAL), TetraVax-DV Vaccine-Admixture 1 (BIOLOGICAL), TetraVax-DV Vaccine-Admixture 2 (BIOLOGICAL), TetraVax-DV Vaccine-Admixture 3 (BIOLOGICAL), TetraVax-DV Vaccine-Admixture 4 (BIOLOGICAL).
Who is sponsoring clinical trial NCT01072786?
This trial is sponsored by National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.